NCT00424528 - Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

235

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Chronic Obstructive Pulmonary DiseaseBronchitisEmphysema

Interventions

DRUG

Arformoterol Tartrate Inhalation Solution

Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.

DRUG

Tiotropium

Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.

DRUG

Arformoterol and Tiotropium

Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.

DRUG

Placebo

Placebo inhalation solution and placebo inhalation powder

Trial Locations (28)

26505

Morgantown

28207

Charlotte

29201

Columbia

29303

Spartanburg

29681

Simpsonville

32435

DeFuniak Springs

32720

DeLand

35501

Jasper

37920

Knoxville

41701

Hazard

42431

Madisonville

43215

Columbus

45242

Cincinnati

48106

Ann Arbor

49007

Kalamazoo

63301

Saint Charles

66606

Topeka

70072

Marrero

70584

Sunset

80909

Colorado Springs

85715

Tucson

92120

San Diego

97213

Portland

97404

Eugene

97504

Medford

98405

Tacoma

02914

East Providence

02865

Lincoln

All Listed Sponsors

lead

Sumitomo Pharma America, Inc.

INDUSTRY